RSV Vaccine (Arexvy)
Are you 60 years old or older? If yes, did you know that Respiratory Syncytial Virus (RSV) can pose a significant threat to their well-being? RSV is a common viral infection that can have severe consequences, especially for infants and older adults. Discover how the RSV vaccine can be a crucial defense against this contagious and potentially harmful virus.
What Is RSV
RSV (respiratory syncytial virus) is a common, contagious virus that affects the lungs and respiratory airways. The virus can affect all ages, but the impact of RSV in older adults is significant. RSV caused an estimated 470,000 hospitalizations and 33,000 deaths in those aged 60 years and above in high-income countries in 2019.
Who Should Get The RSV Vaccine
The RSV vaccine is currently available to patient 60 years and older in Canada. The vaccine was approved by Health Canada at the end of 2023. We expect that both the efficacy and age restrictions of the vaccine will be revised with more data provided to Health Canada but for the moment is restricted to patient’s over 60
What is the RSV Vaccine
The RSV vaccine, (called Arexvy), is an innovative immunization designed to protect against the Respiratory Syncytial Virus (RSV). RSV is a common viral infection that can lead to severe respiratory illness, especially in young children and older adults. Arexvy is a monoclonal antibody, not a traditional vaccine, and it works by providing passive immunity to RSV. Arexvy plays a crucial role in safeguarding the health of vulnerable populations who are at a higher risk of RSV-related complications. It is an essential tool in the ongoing efforts to mitigate the impact of this contagious virus.
